GeoVax Gains EMA Backing for Phase 3 Mpox/Smallpox Vaccine Trial
December 18, 2025 — GeoVax receives EMA Scientific Advice for Phase 3 trial of GEO-MVA mpox/smallpox vaccine, accelerating regulatory path and strengthening global vaccine supply diversification efforts.